Mizuho sees Sarepta Therapeutics (SRPT) sell-off on elevidys death 'likely an overreaction'

Leerink Defending Sarepta Therapeutics (SRPT): 'the stock reaction for SRPT is overdone'

Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments " Bottom Line: Shares of Sarepta (SRPT, OP) are under pressure in the pre-market on the heels of the disclosure of a patient death following Elevidys treatment; while an incredibly sad development for the young man, his family, and the DMD community, it appears that this is a unique event with a very low incidence rate. We continue to view the benefit/risk of Elevidys treatment favorably, and think the stock reaction for... More

JPMorgan Comments on Sarepta Therapeutics (SRPT)

JPMorgan analyst Anupam Rama reiterated an Overweight rating and $187.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "We wanted to pass on our quick thoughts on Sareptas update this morning related to a patient death post treatment with Elevidys. Net-net, sentiment on SRPT shares were already mixed even before the patient death, and certainly with the update... More

TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following Elevidys death

TD Cowen analyst Ritu Baral reiterated a Buy rating and $203.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following today's reported Elevidys death.

The analyst commented, "Our orphan neuromuscular KOL indicated last night at an investor event at MDA that SRPT... More

BofA Defending Sarepta Therapeutics (SRPT): 'Risk-benefit profile of Elevidys remains favorable despite death report'

BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $210.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "Sarepta (SRPT) reported the death of a Duchenne muscular dystrophy (DMD) patient following treatment with Elevidys after suffering acute liver failure. The event was reported to the physician community in a Dear Doctor letter that was sent last night. Management commented the patient had recently had a... More

Sarepta Therapeutics (SRPT) Shares Safety Update on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, shared the following safety update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. We are profoundly saddened to share that a young man with Duchenne muscular dystrophy has passed away following... More

Sarepta Therapeutics (SRPT) Plunges 20% Pre-Open, Reason For Drop Unclear

Sarepta Therapeutics (NASDAQ: SRPT) Plunges 20% Pre-Open, Reason For Drop Unclear